Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program

Hayat, Matthew J.; Howlader, Nadia; Reichman, Marsha E.; Edwards, Brenda K.

doi:10.1634/theoncologist.12-1-20

Cited by 932 publications

(672 citation statements)

References 16 publications

Supporting

Mentioning

614

Contrasting

Unclassified

Order By: Relevance

“…SEER data are considered robust and valid [10,12,13,19,24]. There is 98% completeness in reporting patients with cancer within 22 months of diagnosis across all cancer sites, and annual audits of subsamples of data are issued to evaluate and monitor accuracy [12,24].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Schneiderman

Kliethermes

Nystrom

2017

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Studies suggest that mesenchymal chondrosarcoma is associated with a poorer prognosis and a higher proportion of extraskeletal tumors than conventional chondrosarcoma. However, these investigations have been small heterogeneous cohorts, limiting analysis of prognostic factors. Questions/purposes (1) What is the 5-and 10-year survival rate of patients diagnosed with mesenchymal chondrosarcoma? (2) What is the effect of demographic and tumor characteristics on survival in patients with mesenchymal chondrosarcoma? Methods The Surveillance, Epidemiology, and End Results (SEER) database was used to identify all patients diagnosed with mesenchymal chondrosarcoma from 1973 to 2011. SEER reports survival data on over 8.2 million patients with cancer and has attained 98% completeness in reporting. Using variables within the database, this study designated each patient's tumor as skeletal or extraskeletal and cranial, axial, or appendicular, respectively. Overall survival (OS) was determined for the entire series as well as each group. Median survival was calculated using KaplanMeier methods. Cox proportional hazards regression was used to determine whether demographic and tumor variables affected survival. Two hundred five patients with mesenchymal chondrosarcoma were identified, including 82 (40%) skeletal and 123 (60%) extraskeletal. Results OS for the entire series was 51% (95% confidence interval [CI], 43%-58%) and 43% (95% CI, 35%-51%) at 5 and 10 years, respectively. No difference in OS was detected between extraskeletal and skeletal tumors. KaplanMeier analyses showed OS was worse for tumors in axial locations compared with appendicular and cranial locations. Appendicular tumors demonstrated an OS of 50% (95% CI, 36%-63%) at 5 years and 39% (95% CI, 26%-52%) at 10 years. OS for axial tumors was 37% (95% CI, 25%-49%) and 31% (95% CI, 20%-43%), whereas it was 74% (95% CI, 59%-84%) and 67% (95% CI, 50%-79%) for cranial tumors at 5 and 10 years, respectively. When controlling for age, sex, tumor origin, and tumor location, the presence of metastasis (hazard ratio [HR], 12.38; 95% CI, 5.75-26.65; p \ 0.001) and 1-cm size increase (HR, 1.16; 95% CI, 1.09-1.23; p \ 0.001) were both independently associated with an increased risk of death. Tumor location showed different behaviors depending on patient age. In comparison to cranial tumors at age 20 years, the HR was 5.56 (95% CI, 1.47-21.05; p = 0.01) for axial tumors and 6.26 (95% CI, 1.54-25.42; p = 0.01) for appendicular tumors. At age 60 years, those ratios were 0.10 (95% CI, 0.02-0.55; p = 0.01) and 0.14 (95% CI, 0.04-0.58; p = 0.01), respectively. Conclusions Our data suggest that extraskeletal tumors are more common than previously reported; however, this factor does not have clear prognostic value. Presence of metastatic disease and increased tumor size are the main Each author certifies that he or she, or a member of his or her immediate family, has no funding or commercial associations (eg, consultancies, stock ownership, equity interest, paten...

show abstract

Section: Methodsmentioning

confidence: 99%

“…There is 98% completeness in reporting patients with cancer within 22 months of diagnosis across all cancer sites, and annual audits of subsamples of data are issued to evaluate and monitor accuracy [12,24]. Survival followup is pursued by active and passive methods by each registry for all patients.…”

Section: Methodsmentioning

confidence: 99%

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Schneiderman

Kliethermes

Nystrom

2017

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…Survival analysis in the study by Davies and Welch indicates that mortality rates for thyroid cancer have remained steady at 0.5 deaths per 100,0004, 5. More specific studies of the SEER database utilizing relative survival show different thyroid cancer survival rates based on sex, ethnicity, tumor histology, and stage 6. The 5‐year relative survival rates have increased among women, from 92.7% in 1974 to 97.4% in 20016.…”

Section: Introductionmentioning

confidence: 99%

“…More specific studies of the SEER database utilizing relative survival show different thyroid cancer survival rates based on sex, ethnicity, tumor histology, and stage 6. The 5‐year relative survival rates have increased among women, from 92.7% in 1974 to 97.4% in 20016. However, the annual percentage change (APC) in thyroid cancer mortality rates in men increased by 2.4%, which is among the largest increases in cancer mortality rates of men in the United States 7.…”

Section: Introductionmentioning

confidence: 99%

The impact of marital status at diagnosis on cancer survival in patients with differentiated thyroid cancer

Shi

Lü

et al. 2016

Cancer Medicine

View full text Add to dashboard Cite

Previous studies have revealed that marital status influences the prognosis of patients with various types of cancer. We evaluated the influence of marriage on the survival outcomes in differentiated thyroid cancer (DTC). The Surveillance, Epidemiology and End Results (SEER) database between 2002 and 2012 was used to compare cancer‐specific mortality in different marital status, and in each sex, age, and stage stratification by multivariate Cox regression model. In total, 61,077 eligible patients were identified. The widowed group had the highest proportion of women, elderly patients (≥45 years), and advanced stage III/IV tumor (P = 0.001), but the total thyroidectomy (TT) performed and radioisotopes therapy rates were lower than those in the married group. Married patients had a better cancer‐specific survival (CSS) than the unmarried (P < 0.05). Further analysis showed that widowed patients always presented the lowest CSS compared with other groups. Widowed patients had a significant increased risk for CSS compared with married patients in males [hazard ratio (HR) 2.72, 95% confidence interval (CI): 1.59–4.65, P = 0.001], females (HR 2.02, 95% CI: 2.24–4.06, P = 0.001), young patients (<45, HR 28.12, 95% CI: 3.48–227.25, P = 0.002), elderly patients (≥45, HR 28.12, 95% CI: 2.97, 95% CI: 2.30–3.83, P = 0.001), stage I (HR 8.44, 95% CI: 4.05–17.59, P = 0.001), stage II (HR 3.64, 95% CI: 1.30–10.20, P = 0.014), stage III (HR 2.27, 95% CI: 1.08–4.78, P = 0.031), and stage IV (HR 2.63, 95% CI: 1.94–3.57, P = 0.001). These results showed that unmarried status, especially for widowhood, increased the risk of cancer mortality in DTC patients.

show abstract

“…3 PCa is a disease of aging with a majority of both cases and deaths occurring in men in their 70s (http://seer.cancer.gov/statfacts/html/ prost.html). 4 The extreme differences in incidence and mortality in Asia as compared to the rest of the world have prompted searches for dietary or environmental factors. As for breast cancer, Japanese have extremely low rates that rise if they are first-generation immigrants to the United States and yet further for subsequent generations, suggesting that there are indeed very strong environmental factors.…”

Section: Prostate Cancer (Pca)-global Impact and Risk Factorsmentioning

confidence: 99%

Genetics and genomics of prostate cancer

Dean¹,

Li²

2013

Asian J Androl

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most common malignancies in the world with over 890 000 cases and over 258 000 deaths worldwide each year. Nearly all mortalities from PCa are due to metastatic disease, typically through tumors that evolve to be hormone-refractory or castrate-resistant. Despite intensive epidemiological study, there are few known environmental risk factors, and age and family history are the major determinants. However, there is extreme heterogeneity in PCa incidence worldwide, suggesting that major determining factors have not been described. Genome-wide association studies have been performed and a considerable number of significant, but low-risk loci have been identified. In addition, several groups have analyzed PCa by determination of genomic copy number, fusion gene generation and targeted resequencing of candidate genes, as well as exome and whole genome sequencing. These initial studies have examined both primary and metastatic tumors as well as murine xenografts and identified somatic alterations in TP53 and other potential driver genes, and the disturbance of androgen response and cell cycle pathways. It is hoped that continued characterization of risk factors as well as gene mutation and misregulation in tumors will aid in understanding, diagnosing and better treating PCa.

show abstract

Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program

Cited by 932 publications

References 16 publications

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

The impact of marital status at diagnosis on cancer survival in patients with differentiated thyroid cancer

Genetics and genomics of prostate cancer

Contact Info

Product

Resources

About